Price$22.33-0.09 (-0.38%)
01:30 PM07:45 PM
News · 26 weeks32-46%
2025-12-142026-06-07
Mix2390d
- Insider12(52%)
- SEC Filings7(30%)
- Other3(13%)
- Dividends1(4%)
Latest news
25 items- PRInnoviva to Participate in Upcoming Investor ConferencesInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Format: Fireside chat Date: Monday, June 8, 2026 Time: 1:20 p.m. Eastern Time BTIG Infectious Disease Day Format: 1x1 meetings Date: Tuesday, June 16, 2026 A live webcast of the Goldman Sachs fireside chat can be accessed under "Ev
- INSIDERChief Executive Officer Raifeld Pavel covered exercise/tax liability with 1,130 shares and was granted 1,123 shares, decreasing direct ownership by 0.00% to 285,929 units (SEC Form 4) to satisfy withholding tax4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Financial Officer Basso Stephen was granted 1,123 shares and covered exercise/tax liability with 559 shares, increasing direct ownership by 0.64% to 88,571 units (SEC Form 4) to satisfy withholding tax4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Accounting Officer Zhen Marianne covered exercise/tax liability with 1,127 shares, decreasing direct ownership by 2% to 57,516 units (SEC Form 4) (for withholding tax)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERDirector Linden Josephine was granted 15,194 shares (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERNew insider Linden Josephine claimed no ownership of stock in the company (SEC Form 3)3 - Innoviva, Inc. (0001080014) (Issuer)
- SECSEC Form 8-K filed by Innoviva Inc.8-K - Innoviva, Inc. (0001080014) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Innoviva Inc.SCHEDULE 13D/A - Innoviva, Inc. (0001080014) (Filed by)
- SECSEC Form 10-Q filed by Innoviva Inc.10-Q - Innoviva, Inc. (0001080014) (Filer)
- SECInnoviva Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Innoviva, Inc. (0001080014) (Filer)
- INSIDERDirector Dipaolo Mark was granted 9,786 shares, increasing direct ownership by 7% to 140,492 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Executive Officer Raifeld Pavel was granted 126,646 shares, increasing direct ownership by 80% to 285,936 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Accounting Officer Zhen Marianne was granted 12,766 shares, increasing direct ownership by 28% to 58,643 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Financial Officer Basso Stephen was granted 37,994 shares, increasing direct ownership by 76% to 88,007 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERDirector Schlesinger Sarah J. was granted 9,786 shares, increasing direct ownership by 7% to 140,492 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERDirector Small Derek A was granted 9,786 shares, increasing direct ownership by 28% to 45,035 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERDirector Haimovitz Jules was granted 9,786 shares, increasing direct ownership by 7% to 152,692 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- PRInnoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company ProgressGenerated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created across strategic healthcare asset portfolio Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements.
- SECSEC Form S-8 filed by Innoviva Inc.S-8 - Innoviva, Inc. (0001080014) (Filer)
- SECSEC Form 8-K filed by Innoviva Inc.8-K - Innoviva, Inc. (0001080014) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Innoviva Inc.10-K/A - Innoviva, Inc. (0001080014) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Innoviva Inc.SCHEDULE 13G/A - Innoviva, Inc. (0001080014) (Subject)
- SECSEC Form DEF 14A filed by Innoviva Inc.DEF 14A - Innoviva, Inc. (0001080014) (Filer)
- SECInnoviva Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Innoviva, Inc. (0001080014) (Filer)
- SECSEC Form 10-K filed by Innoviva Inc.10-K - Innoviva, Inc. (0001080014) (Filer)
INVA FAQ
7 questionsWhat does Innoviva Inc. do?
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with...Where does INVA stock trade?
Innoviva Inc. (INVA) is listed on NASDAQ.What sector and industry is INVA in?
Innoviva Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Innoviva Inc. go public?
Innoviva Inc. (INVA) completed its IPO in 2004.What are analysts saying about INVA?
Innoviva Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $3500.00 price target on 2026-02-17. Recent price targets range from $1600.00 to $4500.00.What companies are similar to INVA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare INVA side-by-side with any of them on Quantisnow.How can I track INVA on Quantisnow?
Quantisnow aggregates Innoviva Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INVA to receive live email and push alerts on every new disclosure.